Feiba Vh Immuno
Feiba Vh Immuno Uses, Dosage, Side Effects, Food Interaction and all others data.
Feiba Vh Immuno, also known as FEIBA (factor eight inhibitor bypassing activity), contains several proteins involved in the prothrombinase complex. It is used to control bleeding in hemophilia A and B patients with inhibitors.
FEIBA contains several clotting factors which act at various points in the caogulation cascade to promote thrombosis .
| Trade Name | Feiba Vh Immuno |
| Generic | Anti-inhibitor coagulant complex |
| Anti-inhibitor coagulant complex Other Names | Activated prothrombin complex concentrate, Antiinhibitor coagulant complex, Factor VIII bypassing fraction, Factor VIII inhibitor bypassing activity, Factor VIII inhibitor bypassing fraction |
| Weight | +, |
| Type | Intravenous powder for injection |
| Groups | Approved, Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | United States |
| Last Updated: | September 19, 2023 at 7:00 am |
Uses
Feiba Vh Immuno is a medication used to control bleeding episodes and prevent bleeding episodes in hemophilia A and B.
For use in the control of bleeding episodes, perioperative management, and routine prophylaxis against bleeding episodes in hemophilia A and B patients with inhibitors . It is not indicated in the absence of factor VIII or IX inhibitors.
Feiba Vh Immuno is also used to associated treatment for these conditions: Bleeding caused by Hemophilia A, Bleeding caused by Hemophilia B, Perioperative bleeding caused by Hemophilia A, Perioperative bleeding caused by Hemophilia B
How Feiba Vh Immuno works
Factor VIIa present in FEIBA forms a complex with tissue factor and calcium which converts endogenous and FEIBA contained factor X to Xa . Endogenous and FEIBA contained factor Xa act as parrt of the prothrombinase complex to convert endogenous and FEIBA contained prothrombin to thrombin. Endogenous and FEIBA contained thrombin then cleave fibrinogen to insulouble fibrin and activate factor XIII which covalently cross-links fibrin to form a polymer mesh. FEIBA also contains factor IX and IXa which act as part of the tenase complex to convert factor X to Xa. Thrombin activates factor V, VII, and VIII as part of the amplification phase of the clotting cascade. These events promote the formation of blood clots to prevent or stop bleeding.
Toxicity
FEIBA is associated with increased risk of thromboembolic events such as stroke, myocardial infarction, and deep vein thrombosis .
Food Interaction
No interactions found.Half Life
Plasma half lives of included clotting factors are as follows : Prothrombin - 65h Factor VII - 5h Factor IX - 25h Factor X - 40h
Innovators Monograph
You find simplified version here Feiba Vh Immuno
